Audit: QRS - Potato Starch for Health & Longevity

Audit conducted on 06/09/2026 04:34 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (lines 371–383), time cells to Practical Considerations line 426, benefits/risks to the ER tier headings, gates to Key Interactions & Contraindications (lines 323–347), monitoring rows to the ER biomarker table (lines 458–468).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges are carried through: “No established range; change from own baseline” (marker_8_target), “No consensus target” (marker_9_target), “acknowledging that trial evidence for this is conflicted” (qualitative_item_5).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain absolute framing and thresholds; benefit tiers retain the ER’s population qualifiers (“in inherited cancer risk”, “in chronic kidney disease”).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from Key Interactions & Contraindications; risks draw only from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor bullets appear in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, NCT IDs or brand names in the QRS. The single organism name, Bifidobacterium adolescentis, is the ER’s own interaction bullet (line 337).
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind beyond the template’s AI4L / model line.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER; the At-A-Glance mirrors the ER Conclusion’s phrasing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tier labels and biomarker targets supply the data spine; plain-language At-A-Glance and qualitative markers keep it accessible and actionable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Everything is stated as practice or evidence (“Standard practice, chosen for tolerability rather than efficacy”), never as an instruction to the reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives, no “should”, “must”, “recommended” or “advised” anywhere in the rendered content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence and protocol cells are descriptive statements of what protocols do, not directives.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are only used where they are the marker name itself (e.g., “Alanine aminotransferase”); the At-A-Glance is fully plain.
2.8	Information is presented in a concise and very compact manner	🟢	Every tier is a single semicolon-joined line; gate items are noun phrases; monitoring “Why” cells are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to titrate over four to eight weeks, run a bowel diary, and draw metabolic panels.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, twelve-week assessment window and a nine-marker panel all presume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (e.g., fasting insulin 2–5 µIU/mL) are tighter than conventional lab cut-offs, which targets the optimizing reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance foregrounds responder variability and the dose-dependent tolerability ceiling, the two facts that decide use for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“abdominal distension”, “post-meal endotoxaemia”, “glycated haemoglobin”); the plain wording in At-A-Glance is the ER Conclusion’s own and is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified against the template: lines 440, 477, 519, 539, 545, 556, 575, 579–581, 694, and the eight tier labels at 522/525/528/531 and 559/562/565/568.
3.2	All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# rows are instantiated 9× and 5× respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A masked diff against the template shows differences only at variable substitutions, the frontmatter block, and the repeated monitoring/qualitative rows — no CSS, markup or comment edits.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Target dose”, “Standard preparation” and “Single versus split dosing” are the ER’s bold labels verbatim (ER lines 373, 371, 383); monitoring row labels are the ER biomarker names verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and monitoring labels are verbatim; the three time-to-effect labels are drawn word-for-word from the ER’s own time-to-effect bullet (“fasting glucose and insulin-resistance”, “bowel function”, “microbiome shifts”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiering is carried by the .benefits / .risks CSS palettes and the bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Per-section condensation is applied everywhere: gate items stripped to noun phrases with trimmed example lists, each benefit/risk tier collapsed to one line, monitoring “Target”/”Why” cells shortened from the ER table, qualitative items trimmed. No section carries ER prose at full length.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no value is echoed into visible markup except those the template requires (date, model).
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:02" is quoted, which is required because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: potato_starch_2026-0906-0011_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0906-0408.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: potato_starch_2026-0906-0011_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; git_issue: 5833 and git_user: evipedia-3 are correctly unquoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Potato Starch for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Potato Starch for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/06/2026, the MM/DD/YYYY form of 2026-0906.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the template subline; the ER’s “Also known as” line is correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 condenses ER lines 500–502: mechanism, firmest evidence domains, single-trial findings, responder variability, and the tolerability ceiling.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words — at the limit, not over it.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the five clauses maps to a distinct ER Conclusion passage (escapes digestion → line 500; blood sugar/bowel → 500; liver fat/weight → 500; responder variability → 502; gas and bloating → 502).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “resistant starch”, “short-chain fatty acids” and “type-2” are all replaced with plain wording (“mostly escapes digestion”, “feeds large-bowel bacteria”).
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“single trials point to” carries no name, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear in the At-A-Glance.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items map one-to-one to the ER’s “Populations who should avoid Potato Starch” list (ER lines 343–347).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Line 541: five discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— absolute contraindication” tails and the rationale clauses (“residual potato protein cannot be excluded…”, “given the unheated raw powder”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(retained solids at four hours)”, “(below 500 cells/µL)”, “within four to six weeks”, “with luminal narrowing” and “outside a supervised trial” are all retained in condensed form.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication parentheticals.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five such populations and the section is correctly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –>	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one to the ER’s nine interaction bullets (ER lines 323–339).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine interaction bullets carried; no overlap with the five contraindication items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Line 547: nine discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Caution —”, “Monitor —” and “Potentiating rather than harmful —” tail is stripped, along with the Li et al. citation attached to the probiotics bullet.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every bullet retains its example-drug parenthetical, trimmed to the leading representatives (e.g., “(levothyroxine, warfarin, digoxin, lithium)”, “(psyllium, polyethylene glycol)”); none is dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction parentheticals.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such interactions and the section is correctly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –>	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol bullets at lines 371, 373 and 383.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Target dose, standard preparation and split dosing are the three decisions a user must make; minimum effective duration is carried separately in the Time to Effect row rather than duplicated here.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; e.g. action_1_sub “24–48 g powder, about 16–32 g resistant starch, reached over four to eight weeks” matches ER line 373.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The three clauses of the ER’s “Time to effect” bullet (line 426) — bowel change within days, microbiome shift at one to two weeks, glycaemic effects beyond eight weeks — are each given a cell.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered fasting glucose/insulin resistance → bowel function → microbiome shift, matching the ER’s High-tier benefit ordering (ER lines 155, 167) with the non-tiered microbiome readout last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated with ER-sourced values (“Beyond 8 weeks”, “Within days”, “1–2 weeks”) and supporting subtext.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen items correspond to the thirteen ER benefit headings across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to a noun phrase; no Magnitude: figures, no “⚠️ Conflicted” markers, no citations.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER, so no tier needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items correspond to the eight ER risk headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 558–569.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to a noun phrase; no Magnitude: figures, no “⚠️ Conflicted” markers, no citations.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s “(a disordered gut microbiome)” gloss is correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no tier needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All nine rows derive from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 458–468).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present, in ER order, with targets preserved (e.g., “10–26 U/L (men), 8–22 U/L (women)”, “Below 1.0”).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 688 condenses ER lines 454 and 456: baseline panel, bowel diary at four weeks, metabolic panel at twelve weeks after eight at target dose, then every six to twelve months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items derive from the ER’s “Qualitative markers worth tracking” list (ER lines 472–476).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present, in ER order: stool form, bloating score, flatulence frequency, post-meal energy stability, appetite.

Issues 06/09/2026 04:34

Pass rate 100.00%. No issues found.

Issues 06/09/2026 04:28

1. 8.5 — Dropped “Known or suspected” qualifier: The contraindication at line 541 reads “Mechanical bowel obstruction, or stricturing Crohn’s disease with luminal narrowing”, dropping the ER’s certainty qualifier “Known or suspected” (ER line 344) and narrowing the decision gate to confirmed obstruction only.

Fixes 06/09/2026 04:28

1. 8.5 — Restored “Known or suspected” qualifier: The first contraindication item was changed from “Mechanical bowel obstruction, or stricturing Crohn’s disease with luminal narrowing” to “Known or suspected mechanical bowel obstruction, or stricturing Crohn’s disease with luminal narrowing”, restoring the ER’s certainty qualifier.

Issues 06/09/2026 04:21

1. 2.15 — Consumer-grade dose abbreviation: [action_1_value] at line 447 reads “2–4 tbsp daily”, using the kitchen abbreviation “tbsp” where the ER writes “2–4 tablespoons of powder daily” (ER line 373).
2. 4.3 — Two interaction labels altered: In [caution_items] (line 547) the ER bold label “Over-the-counter bulk laxatives and osmotics” (ER line 331) is abbreviated to “Bulk laxatives and osmotics”, and “Competing dietary interventions” (ER line 339) is paraphrased to “Competing diets”.

Fixes 06/09/2026 04:21

1. 2.15 — Consumer-grade dose abbreviation: [action_1_value] changed from “2–4 tbsp daily” to “2–4 tablespoons daily”, matching the ER’s own wording.
2. 4.3 — Two interaction labels restored: In [caution_items], “Bulk laxatives and osmotics” was restored to the ER label “Over-the-counter bulk laxatives and osmotics”, and “Competing diets” to “Competing dietary interventions”.

Issues 06/09/2026 04:10

1. 4.5 — Content exceeds one A4 page: At the template’s print settings the sheet renders to roughly two A4 pages; the Key Interactions gate (line 547, ~21 wrapped lines), the nine-row Monitoring table with full-sentence target cells (lines 585–683), and the full-sentence protocol/time subs and qualitative items (lines 450, 461, 472, 489, 697–710) each carry more text than the one-page budget allows.

Fixes 06/09/2026 04:10

1. 4.5 — Key Interactions gate condensed: Trimmed the parenthetical example drug lists to the two or three most representative agents per item (e.g. “psyllium, methylcellulose, polyethylene glycol, magnesium hydroxide” → “psyllium, polyethylene glycol”) and shortened three item stems, keeping every interaction and at least one named example.
2. 4.5 — Contraindication qualifiers tightened: Shortened the stop-gate parentheticals and stems without dropping any threshold or time window (e.g. “Profound neutropenia (absolute neutrophil count below 500 cells/µL) outside a supervised trial protocol” → “Profound neutropenia (below 500 cells/µL) outside a supervised trial”).
3. 4.5 — Protocol and time-to-effect subs shortened: Reduced all three action subs and the first time sub to single short clauses, and removed the evening-dosing sentence that had been appended to the “Single versus split dosing” cell.
4. 4.5 — Long Monitoring cells compressed: Rewrote the two full-sentence target cells as “No established range; change from own baseline” and “No consensus target; change from own pre-intervention peaks”, and shortened the marker 5 and marker 6 “Why” cells.
5. 4.5 — Cadence and qualitative items tightened: Condensed the monitoring cadence sentence and qualitative items 1 and 3 so each renders on a single line.